Garden Insiders Sold Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Recently?

Investors may wish to note that the Chief Financial Officer of Fulgent Genetics, Inc., Paul Kim, recently netted US$64k from selling stock, receiving an average price of US$35.89. On the bright side, that’s just a small sale and only reduced their holding by 2.2%.

Check out our latest analysis for Fulgent Genetics

Fulgent Genetics Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the COO & President, Jian Xie, sold US$583k worth of shares at a price of US$58.29 per share. We generally don’t like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was well above the current price of US$37.05. So it may not tell us anything about how insiders feel about the current share price.

In the last year Fulgent Genetics insiders did not buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGM:FLGT Insider Trading Volume November 21st 2022

If you are like me, then you will note want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of Fulgent Genetics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Fulgent Genetics insiders own 32% of the company, currently worth about US$363m based on the recent share price. This kind of significant ownership by insiders generally increases the chance that the company is run in the interest of all shareholders.

So What Do The Fulgent Genetics Insider Transactions Indicate?

Insiders sold stock recently, but they haven’t been buying. And even if we look at the last year, we didn’t see any purchases. The company boasts high insider ownership, but we’re a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Fulgent Genetics. For example, Fulgent Genetics has 3 warning signs (and 1 which doesn’t sit too well with us) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Valuation is complex, but we’re helping make it simple.

Find out whether Fulgent Genetics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take into account your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Leave a Comment

Your email address will not be published. Required fields are marked *

%d bloggers like this: